These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29512735)

  • 21. Breast-conserving surgery after chemotherapy: value of MDCT for determining tumor distribution and shrinkage pattern.
    Tozaki M; Kobayashi T; Uno S; Aiba K; Takeyama H; Shioya H; Tabei I; Toriumi Y; Suzuki M; Fukuda K
    AJR Am J Roentgenol; 2006 Feb; 186(2):431-9. PubMed ID: 16423949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer.
    Ko ES; Han BK; Kim RB; Ko EY; Shin JH; Hahn SY; Nam SJ; Lee JE; Lee SK; Im YH; Park YH
    Ann Surg Oncol; 2013 Aug; 20(8):2562-8. PubMed ID: 23463090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
    Charehbili A; Wasser MN; Smit VT; Putter H; van Leeuwen-Stok AE; Meershoek-Klein Kranenbarg WM; Liefers GJ; van de Velde CJ; Nortier JW; Kroep JR
    Eur J Surg Oncol; 2014 Oct; 40(10):1216-21. PubMed ID: 25150151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Computer-aided detection applied to breast MRI: assessment of CAD-generated enhancement and tumor sizes in breast cancers before and after neoadjuvant chemotherapy.
    Demartini WB; Lehman CD; Peacock S; Russell MT
    Acad Radiol; 2005 Jul; 12(7):806-14. PubMed ID: 16039534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging--comparison with contrast-enhanced MR imaging and pathologic findings.
    Woodhams R; Kakita S; Hata H; Iwabuchi K; Kuranami M; Gautam S; Hatabu H; Kan S; Mountford C
    Radiology; 2010 Feb; 254(2):357-66. PubMed ID: 20093508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [MRI evaluation of residual breast carcinoma after neoadjuvant chemotherapy].
    Morvan A; de Korvin B; Bouriel C; Carsin A; Tas P; Bendavid C; Dupré PF; Kerbrat P; Mesbah H; Poree P; Levêque J
    J Radiol; 2010 Jun; 91(6):693-9. PubMed ID: 20808270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy.
    Peintinger F; Kuerer HM; Anderson K; Boughey JC; Meric-Bernstam F; Singletary SE; Hunt KK; Whitman GJ; Stephens T; Buzdar AU; Green MC; Symmans WF
    Ann Surg Oncol; 2006 Nov; 13(11):1443-9. PubMed ID: 17028770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The usefulness of Tc-99m-tetrofosmin SPECT/CT in the detection of residual tumors and axillary lymph node metastases in breast cancer patients following neoadjuvant therapy.
    Spanu A; Sanna D; Chessa F; Farris A; Nuvoli S; Madeddu G
    Clin Nucl Med; 2011 Nov; 36(11):997-1002. PubMed ID: 21975387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CT findings of breast cancer with clinically complete response following neoadjuvant chemotherapy--histological correlation.
    Ogawa Y; Nishioka A; Kubota K; Kariya S; Yoshida S; Maeda H; Tanaka Y; Moriki T; Tochika N
    Oncol Rep; 2003; 10(5):1411-5. PubMed ID: 12883716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
    Rajan R; Poniecka A; Smith TL; Yang Y; Frye D; Pusztai L; Fiterman DJ; Gal-Gombos E; Whitman G; Rouzier R; Green M; Kuerer H; Buzdar AU; Hortobagyi GN; Symmans WF
    Cancer; 2004 Apr; 100(7):1365-73. PubMed ID: 15042669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy.
    Ataseven B; Lederer B; Blohmer JU; Denkert C; Gerber B; Heil J; Kühn T; Kümmel S; Rezai M; Loibl S; von Minckwitz G
    Ann Surg Oncol; 2015 Apr; 22(4):1118-27. PubMed ID: 25297900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Residual Pure Intralymphatic Breast Carcinoma Following Neoadjuvant Chemotherapy Is Indicative of Poor Clinical Outcome, Even in Node-Negative Patients.
    Cheng E; Ko D; Nguyen M; Moo TA; Andreopoulou E; Hoda SA; D'Alfonso TM
    Am J Surg Pathol; 2017 Sep; 41(9):1275-1282. PubMed ID: 28654428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy.
    Rosen EL; Blackwell KL; Baker JA; Soo MS; Bentley RC; Yu D; Samulski TV; Dewhirst MW
    AJR Am J Roentgenol; 2003 Nov; 181(5):1275-82. PubMed ID: 14573420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cervical cancer response to neoadjuvant chemoradiotherapy: MRI assessment compared with surgery.
    Gui B; Valentini AL; Miccò M; D'Agostino GR; Tagliaferri L; Zannoni GF; Fanfani F; Manfredi R; Bonomo L
    Acta Radiol; 2016 Sep; 57(9):1123-31. PubMed ID: 26622060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy.
    De Los Santos J; Bernreuter W; Keene K; Krontiras H; Carpenter J; Bland K; Cantor A; Forero A
    Clin Breast Cancer; 2011 Oct; 11(5):312-9. PubMed ID: 21831721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive value of axillary nodal imaging by magnetic resonance imaging based on breast cancer subtype after neoadjuvant chemotherapy.
    Steiman J; Soran A; McAuliffe P; Diego E; Bonaventura M; Johnson R; Ahrendt G; McGuire K
    J Surg Res; 2016 Jul; 204(1):237-41. PubMed ID: 27451892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy.
    Marinovich ML; Houssami N; Macaskill P; Sardanelli F; Irwig L; Mamounas EP; von Minckwitz G; Brennan ME; Ciatto S
    J Natl Cancer Inst; 2013 Mar; 105(5):321-33. PubMed ID: 23297042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimally Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment: A New Concept.
    Pfob A; Cai L; Schneeweiss A; Rauch G; Thomas B; Schaefgen B; Kuemmel S; Reimer T; Hahn M; Thill M; Blohmer JU; Hackmann J; Malter W; Bekes I; Friedrichs K; Wojcinski S; Joos S; Paepke S; Degenhardt T; Rom J; Rody A; van Mackelenbergh M; Banys-Paluchowski M; Große R; Reinisch M; Karsten MM; Sidey-Gibbons C; Wallwiener M; Golatta M; Heil J
    Ann Surg Oncol; 2024 Feb; 31(2):957-965. PubMed ID: 37947974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How do we measure a residual tumor size in histopathology (the gold standard) after neoadjuvant chemotherapy?
    Apple SK; Suthar F
    Breast; 2006 Jun; 15(3):370-6. PubMed ID: 16185870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.